Sanofi appoints Ameet Nathwani Chief Digital Officer
12 Février 2019 - 7:00AM
|
Press Release
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
|
Sanofi appoints Ameet Nathwani Chief Digital
Officer
-
Ameet Nathwani, M.D., will also continue to
serve as Executive Vice-President, Chief Medical Officer
Paris - February 12, 2019 - Sanofi has
appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition
to his current role of Executive Vice President, Chief Medical
Officer.
As Chief Digital Officer, Dr.
Nathwani will be responsible for enhancing Sanofi's strategy to
integrate digital technologies and medical science to ultimately
improve patient outcomes. His mandate will include scaling up
Sanofi's ongoing portfolio of digital initiatives by developing
broad external partnerships, building out internal infrastructures,
and exploring new business opportunities for Sanofi in the digital
space.
"Over the last two years, we have made fast progress in creating an
innovative portfolio of digital initiatives and novel
partnerships," said Olivier Brandicourt, Chief Executive
Officer at Sanofi. "With Ameet's wide experience
in digital health and analytics, we will be able to further advance
our capabilities to re-invent not only the way we discover and
develop medicines but the types of future products we may offer to
patients around the world."
Dr. Nathwani joined Sanofi in May 2016 as Chief Medical
Officer.
A U.K. citizen, born in Uganda and
educated in the U.K., Dr. Nathwani has more than 20 years of
experience in the pharmaceutical industry. Prior to joining Sanofi,
Dr. Nathwani was the Global Head of Medical Affairs, Novartis
Pharma AG and served as an extended member of the Pharma Executive
Committee where he led the establishment of a Real World Evidence
Center of Excellence and Digital Medicine capability.
He joined Novartis in 2004 as the
Senior Vice President and Global Development Head of the
Cardiovascular and Metabolic Franchise and over the period of 11
years held a number of senior development and commercial positions
including the Global Head of the Critical Care Business Franchise.
Dr. Nathwani began his pharmaceutical career in 1994 when he joined
Glaxo Group Research. From 1994 to 2004, he held increasingly
senior global functional and franchise leadership roles in research
and development in Glaxo, SmithKline Beecham and GlaxoSmithKline,
both in Europe and the U.S.
Dr. Nathwani qualified in medicine
in 1987 in London, acquired his specialization in Cardiology at a
number of University Hospitals in London, and has a diploma in
Pharmaceutical Medicine and an executive Master's Degree in
Business Administration.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Quentin
Vivant
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
|
Press release (pdf)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024